Bariatric Surgery in Patients With Schizophrenia

NCT ID: NCT06043206

Last Updated: 2023-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-01

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is known that schizophrenia is associated with obesity in a significant number of patients and it implies a poor prognostic factor, with weight loss being important in this population. However, data about the prognosis of weight loss surgery in subjects with schizophrenia is scant.

Hypothesis: Bariatric surgery in subjects with schizophrenia leads to an improvement in weight and cardiometabolic comorbidities similar to that of subjects without schizophrenia Main goal: To study the evolution after bariatric surgery in patients with obesity and schizophrenia Design: Multicenter retrospective case control study. Disease under study: Schizophrenia and Obesity Methodology: Retrospective observational study Study population and total number of subjects Cases: Patients with schizophrenia and obesity undergoing bariatric surgery. (number: all cases collected within the GOSEEN group).

Controls: Patients without psychiatric pathology matched by age, sex, body mass index and type of surgery and in a 4:1 ratio to cases.

Calendar. Expected duration of the study. 12 months ethical considerations Informed consent will be obtained from patients who are currently being followed up at the reference centers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

THEORETICAL FRAMEWORK. PROBLEM STATEMENT:

Background Obesity affects approximately 45-55% of patients with schizophrenia (1). Weight gain in these patients may be due to different factors such as the use of antipsychotic drugs with an unfavorable metabolic profile, the coexistence of sleep disorders or negative cognitive symptoms that often translate into a more sedentary lifestyle and alterations in eating behavior, among others (2). The coexistence of obesity and its comorbidities in this group of patients significantly worsens both their physical and mental health (3). In fact, cardiovascular disease is one of the main causes of mortality in patients with schizophrenia (4).

Lifestyle interventions, while they may be effective in people with schizophrenia (5), often fall short of achieving weight goals. At present, obesity surgery represents the most effective treatment in terms of weight loss and resolution of comorbidities, being indicated in cases of patients with a body mass index (BMI) \> 35 kg/m2 with comorbidities or BMI \> 40 Kg/m2 with/without comorbidities. However, the access of patients with schizophrenia to bariatric surgery techniques is usually limited by different factors such as fear of a possible worsening of the underlying disease, or a lower weight loss in this population, among others. In addition, clinical practice guidelines recommend that all patients with psychiatric pathologies be evaluated in a regulated manner prior to surgery (6), although the content of this evaluation and the criteria for declining or accepting surgery are not clear. Although the course of schizophrenia is variable and its symptoms may be stable without being a clear contraindication for bariatric surgery, in actual practice, a considerable number of professionals contraindicate bariatric surgery in the presence of a psychotic disorder (7).

For these reasons, data on the efficacy of bariatric surgery in patients with schizophrenia are scarce and limited to very small case series with short-term follow-up (2,8,9). Our objective is therefore to carry out a multicenter retrospective study that allows us to study the long-term evolution after bariatric surgery in a large series of patients, focusing not only on weight evolution but also on the long-term evolution of psychiatric pathology.

Justification It is necessary to have information about the prognosis of subjects with severe obesity and schizophrenia who undergo bariatric surgery. This knowledge will make it possible to establish clear guidelines for action in these cases.

Research questions What is the long-term outcome after bariatric surgery in subjects with schizophrenia? Hypothesis Bariatric surgery in subjects with schizophrenia leads to an improvement in weight and cardiometabolic comorbidities similar to that of subjects without schizophrenia

GOALS:

Main goal:

To study the short (first year after bariatric surgery) and long-term (up to 5 years of follow-up after bariatric surgery) evolution in terms of weight loss of patients with obesity and schizophrenia who underwent bariatric surgery in Spain and compare it with the evolution of patients without psychiatric disorder.

Secondary objectives:

* Determine the casuistry of patients, with special interest in the characteristics of the underlying psychiatric pathology (years of evolution, clinical stability criteria, pharmacological treatment...).
* To Analyze the evolution of obesity comorbidities.
* To Analyze the evolution of psychiatric pathology after bariatric surgery: (decompensation, drug treatment...)
* To analyze the frequency of early (\<30 days post-surgery) or late (\>30 days post-surgery) post-surgical complications.

METHODS:

Study design Retrospective case-control study.

Expected sample size All cases detected in Spanish territory The minimum number of cases expected will be 10 patients based on the low casuistry of the problem. The number of patients in the control group will be x4 that in the study group.

Methodology. Information sources The study population will be identified in each center in the usual specialty consultations or by searching the databases of each center. Review of medical records in search of the specified variables (retrospective observational study).

Data Management and Analysis The coordinating researcher (Dra Inka Miñambres Donaire) will be responsible for the creation of the database and its exploitation. The database will be created in Excell format and the SPSS program will be used for statistical analysis. The statistics will be mainly descriptive. For cases in which it is decided to compare groups, normality tests will be used to establish the behavior of the variables and parametric/non-parametric tests will be used as appropriate.

Data collection The researcher will guarantee the accuracy and integrity of the data, as well as all the reports that are required. The data included in the Data Collection Notebook (CRD), which are derived from source documents, will be consistent with those documents or otherwise the discrepancies will be justified.

The researcher will keep the study documents until at least 5 years after completion.

At the request of the monitor, auditor, ethics committee or health authority, the researcher will have available all the files related to the study, allowing direct access to the data or source documents for monitoring, auditing, review by the ethics committee, as well as the inspection of the trial by the competent authorities.

Limitations of the design, the source of information and the methods of analysis

The main limitation of the study is its retrospective nature. However, the study design is adequate given the low frequency of the pathology.

Data confidentiality Regarding the confidentiality of the study data, the provisions of Organic Law 3/2018, of December 5, on the Protection of Personal Data and Guarantee of Digital Rights and the General Regulation (EU) on Data Protection will be followed. 2016/679.

Interference with physician's prescribing habits As it is a retrospective study, there will be no interference with the prescribing habits of the doctor.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases Obesity and schizophrenia

Patients with schizophrenia and obesity undergoing bariatric surgery

Bariatric Surgery

Intervention Type PROCEDURE

Bariatric Surgery

Controls

Patients without psychiatric pathology matched by age, sex, BMI and type of surgery and in a 4:1 ratio to cases.

Bariatric Surgery

Intervention Type PROCEDURE

Bariatric Surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bariatric Surgery

Bariatric Surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with severe obesity undergoing bariatric surgery and with follow-up in Spanish territory.
2. Patient with schizophrenia or schizoaffective disorder.


Controls: in a 4:1 ratio with cases

Inclusion) Both criteria must be met:

1. Patients with severe obesity undergoing bariatric surgery and with follow-up in Spanish territory.
2. Absence of psychiatric pathology
3. Paired with the cases by age, sex, BMI before surgery and type of surgery.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital del Mar

OTHER

Sponsor Role collaborator

Hospital Universitario Reina Sofia de Cordoba

OTHER_GOV

Sponsor Role collaborator

Parc Taulí Hospital Universitari

OTHER

Sponsor Role collaborator

University Hospital A Coruña

OTHER

Sponsor Role collaborator

Hospital General Universitario Gregorio Marañon

OTHER

Sponsor Role collaborator

University of Navarrra Hospital (Clinica Universitaria)

OTHER

Sponsor Role collaborator

Hospital Clinic of Barcelona

OTHER

Sponsor Role collaborator

León University Assistance Complex, Leon, Spain

UNKNOWN

Sponsor Role collaborator

Valle del Nalón Hospital, Asturias, Spain

UNKNOWN

Sponsor Role collaborator

Complejo Hospitalario Universitario de Vigo

OTHER

Sponsor Role collaborator

Hospital Arnau de Vilanova

OTHER

Sponsor Role collaborator

Hospital San Carlos, Madrid

OTHER

Sponsor Role collaborator

Hospital Universitari de Bellvitge

OTHER

Sponsor Role collaborator

Hospitales Universitarios Virgen del Rocío

OTHER

Sponsor Role collaborator

Hospital Regional de Malaga

OTHER

Sponsor Role collaborator

Germans Trias i Pujol Hospital

OTHER

Sponsor Role collaborator

Hospital Universitario Virgen Macarena

OTHER

Sponsor Role collaborator

Hospital Mutua de Terrassa

OTHER

Sponsor Role collaborator

Hospital Son Llatzer

OTHER

Sponsor Role collaborator

University Hospital of Girona Dr. Josep Trueta

NETWORK

Sponsor Role collaborator

University Hospital of the Canary Islands, Tenerife, Spain

UNKNOWN

Sponsor Role collaborator

Hospital Virgen de la Luz

OTHER

Sponsor Role collaborator

Hospital Universitario Virgen de la Victoria

OTHER

Sponsor Role collaborator

Viladecans Hospital, Barcelona, Spain

UNKNOWN

Sponsor Role collaborator

Hospital Universitario Doctor Peset

OTHER

Sponsor Role collaborator

Hospital Universitari Sant Joan de Reus

OTHER

Sponsor Role collaborator

General Hospital, Vic, Spain

UNKNOWN

Sponsor Role collaborator

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital of Santa Creu i Sant Pau

Barcelona, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IIBSP-BAR-2022-30

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.